Abstract
During the past decade, nucleotide analogs have emerged as novel antiviral agents against hepatitis B virus. Adefovir dipivoxil, a prototype phosphonate analog, has been approved for chronic hepatitis B virus therapy, and additional phosphonate analogs and di- and tri-nucleotides are under development. Several innovative prodrug derivatizations have also been reported to improve the oral bioavailability of nucleotide analogs, which usually carry a negative charge.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antiviral Agents / chemistry
-
Antiviral Agents / metabolism
-
Antiviral Agents / pharmacology*
-
Antiviral Agents / therapeutic use
-
Hepatitis B virus / drug effects*
-
Hepatitis B virus / genetics*
-
Humans
-
Nucleotides / chemistry
-
Nucleotides / metabolism
-
Nucleotides / pharmacology*
-
Nucleotides / therapeutic use
-
Prodrugs / chemistry
-
Prodrugs / metabolism
Substances
-
Antiviral Agents
-
Nucleotides
-
Prodrugs